EA200900581A1 - Способ лечения демиелинизирующего заболевания (варианты), способ стимулирования ремиелинизации, доставочное устройство (варианты) и набор, способ инструктирования больного, страдающего демиелинизирующим заболеванием - Google Patents

Способ лечения демиелинизирующего заболевания (варианты), способ стимулирования ремиелинизации, доставочное устройство (варианты) и набор, способ инструктирования больного, страдающего демиелинизирующим заболеванием

Info

Publication number
EA200900581A1
EA200900581A1 EA200900581A EA200900581A EA200900581A1 EA 200900581 A1 EA200900581 A1 EA 200900581A1 EA 200900581 A EA200900581 A EA 200900581A EA 200900581 A EA200900581 A EA 200900581A EA 200900581 A1 EA200900581 A1 EA 200900581A1
Authority
EA
Eurasian Patent Office
Prior art keywords
options
diseases
remielinization
demielinizing
stimulating
Prior art date
Application number
EA200900581A
Other languages
English (en)
Inventor
Джеффри Браунинг
Дженни Пи-Уай Тин
Original Assignee
Байоджен Айдек Эмэй Инк.
Юнивесити Оф Нос Кэрэлайнэ Эт Чапел Хилл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Эмэй Инк., Юнивесити Оф Нос Кэрэлайнэ Эт Чапел Хилл filed Critical Байоджен Айдек Эмэй Инк.
Publication of EA200900581A1 publication Critical patent/EA200900581A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к способам лечения демиелинизирующих заболеваний, например, рассеянного склероза, с применением растворимого лимфотоксинового бета-рецептора (LTβR) в качестве ингибитора лимфотоксинового пути.
EA200900581A 2006-10-20 2007-10-18 Способ лечения демиелинизирующего заболевания (варианты), способ стимулирования ремиелинизации, доставочное устройство (варианты) и набор, способ инструктирования больного, страдающего демиелинизирующим заболеванием EA200900581A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86234306P 2006-10-20 2006-10-20
PCT/US2007/081761 WO2008049053A2 (en) 2006-10-20 2007-10-18 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor

Publications (1)

Publication Number Publication Date
EA200900581A1 true EA200900581A1 (ru) 2009-08-28

Family

ID=39314832

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900581A EA200900581A1 (ru) 2006-10-20 2007-10-18 Способ лечения демиелинизирующего заболевания (варианты), способ стимулирования ремиелинизации, доставочное устройство (варианты) и набор, способ инструктирования больного, страдающего демиелинизирующим заболеванием

Country Status (14)

Country Link
US (2) US8067375B2 (ru)
EP (2) EP2073833A2 (ru)
JP (3) JP2010506955A (ru)
KR (2) KR20090083958A (ru)
CN (2) CN101653599A (ru)
AU (1) AU2007311052B2 (ru)
BR (1) BRPI0718283A2 (ru)
CA (1) CA2666934A1 (ru)
EA (1) EA200900581A1 (ru)
IL (1) IL198196A0 (ru)
MX (1) MX2009004134A (ru)
NZ (1) NZ576424A (ru)
SG (2) SG178002A1 (ru)
WO (1) WO2008049053A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2139509A2 (en) * 2007-03-15 2010-01-06 Biogen Idec MA, Inc. Treatment of autoimmune disorders
BR112012015876A2 (pt) * 2009-12-17 2016-11-16 Sanofi Sa modelo animal expressando luciferase sob controle do promotor de proteína básica de mielina (mbp-luci) e utilização do modelo bioliminescência imagem in vivo
CN105050621B (zh) * 2013-02-14 2018-10-23 康奈尔大学 防止和治疗多发性硬化症的方法
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
JP6382499B2 (ja) 2013-10-31 2018-08-29 株式会社Ｎｔｔドコモ 無線基地局、ユーザ端末及び無線通信方法
CN104922670A (zh) * 2015-05-06 2015-09-23 武汉奥斯梅得生物医药有限公司 融合免疫蛋白在制备治疗多发性硬化症药物中的应用
CN107213456B (zh) * 2017-05-25 2020-08-21 苏州华测生物技术有限公司 淋巴毒素衍生物的新用途
WO2020123861A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020180624A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
CN112305226A (zh) * 2019-07-31 2021-02-02 首都医科大学附属北京天坛医院 抗人gfap自身抗体检测试剂盒及制备方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4758549A (en) * 1983-12-13 1988-07-19 Kabushiki Kaisha Mayashibara Seibutsu Kagaku Kenkyujo Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses
US4959457A (en) * 1984-05-31 1990-09-25 Genentech, Inc. Anti-lymphotoxin
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8529014D0 (en) * 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
CA2001756A1 (en) 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1991000347A1 (en) 1989-07-04 1991-01-10 Novo Nordisk A/S Method of producing proteins with fviii activity and/or fviii derivatives
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
EP0536299B1 (en) * 1990-06-27 2001-06-06 Biogen, Inc. Surface complexed lymphotoxin
NZ240718A (en) 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin analogues carrying mutations in the alpha-helix-1 region
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
JPH08507201A (ja) 1992-12-04 1996-08-06 バイオジェン，インコーポレイテッド リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用
US5691196A (en) 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5726039A (en) * 1994-07-21 1998-03-10 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Vectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
PL185364B1 (pl) 1995-01-26 2003-04-30 Biogen Kompozycje farmaceutyczne do leczenia albo zmniejszenia zaawansowania, ciężkości albo skutków powstawania nowotworu
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
GB9514518D0 (en) 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
CN1233189A (zh) 1996-05-08 1999-10-27 弗·哈夫曼-拉罗切有限公司 用TNFR-Ig治疗哮喘
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
PT954333E (pt) 1996-10-25 2006-10-31 Biogen Idec Inc Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
EP0948543A1 (en) 1996-12-12 1999-10-13 Genentech, Inc. Hvem polypeptides and uses thereof
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
IL137489A0 (en) 1998-01-30 2001-07-24 Univ New York Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
CA2325022A1 (en) 1998-04-16 1999-10-21 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
DE69931944T2 (de) * 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
AR035352A1 (es) * 2000-10-13 2004-05-12 Biogen Inc Anticuerpos anti-lt-beta-r humanizados
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
EP1583503A4 (en) * 2002-12-20 2006-08-09 Biogen Idec Inc POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF
BR0317573A (pt) * 2002-12-20 2005-11-22 Biogen Idec Inc Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos
EP1756162A1 (en) * 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
CA2655411A1 (en) 2006-06-15 2007-12-21 Biogen Idec Ma Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
EP2139509A2 (en) * 2007-03-15 2010-01-06 Biogen Idec MA, Inc. Treatment of autoimmune disorders

Also Published As

Publication number Publication date
CN101653599A (zh) 2010-02-24
WO2008049053A3 (en) 2008-10-23
IL198196A0 (en) 2011-08-01
AU2007311052B2 (en) 2014-01-16
JP2009242419A (ja) 2009-10-22
AU2007311052A1 (en) 2008-04-24
CA2666934A1 (en) 2008-04-24
MX2009004134A (es) 2009-08-12
NZ576424A (en) 2012-09-28
SG178002A1 (en) 2012-02-28
KR20090071652A (ko) 2009-07-01
JP2013227340A (ja) 2013-11-07
BRPI0718283A2 (pt) 2013-11-12
US8067375B2 (en) 2011-11-29
JP2010506955A (ja) 2010-03-04
EP2311481A3 (en) 2013-10-16
WO2008049053A2 (en) 2008-04-24
EP2073833A2 (en) 2009-07-01
CN101600450A (zh) 2009-12-09
US20120244153A1 (en) 2012-09-27
SG154441A1 (en) 2009-08-28
EP2311481A2 (en) 2011-04-20
US20100099608A1 (en) 2010-04-22
KR20090083958A (ko) 2009-08-04

Similar Documents

Publication Publication Date Title
EA200900581A1 (ru) Способ лечения демиелинизирующего заболевания (варианты), способ стимулирования ремиелинизации, доставочное устройство (варианты) и набор, способ инструктирования больного, страдающего демиелинизирующим заболеванием
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
EA201070247A1 (ru) Ингибиторы протеасом
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
EA200900959A1 (ru) Ингибиторы мек
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EA200870424A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
NO20054958L (no) Substitulerte aminokarboksylsyrer
EA201070039A1 (ru) Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201290189A1 (ru) Человеческие нейтрализующие антитела анти-ngf в качестве селективных ингибиторов метаболических путей фактора роста нервов
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
NO20090608L (no) Tyrosinkinaseinhibitorer
MX2009009636A (es) Metodos para tratar enfermedades oftalmicas.
DE602005014566D1 (de) Chinolinon-carboxamid-verbindungen